Clinical Trial Update: An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013) [Phase 2]

View source ↗

Summary

Phase 2 trial of vorinostat (suberoylanilide hydroxamic acid) for relapsed diffuse large B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Vorinostat (vorinostat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: B-cell Lymphoma | Phase 2 | Status: COMPLETED